(MedPage Today) — SAN ANTONIO — Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) significantly improved progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer…
Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118958
Author :
Publish date : 2025-12-11 17:19:00
Copyright for syndicated content belongs to the linked Source.
